Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer

Journal of Cellular Biochemistry

Volumn 111, Issue 4, 2010, Pages 782-790

  Burrell, Rebecca A ^a   Juul, Nicolai ^b   Johnston, Stephen R ^c   Reis Filho, Jorge S ^d   Szallasi, Zoltan ^b,e   Swanton, Charles ^a,c  

^a London Research Institute   (United Kingdom)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; CEP17; Chromosomal instability; Drug resistance; HER2; Microtubule; Tumour heterogeneity

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; LAPATINIB; PACLITAXEL; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATTENUATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CHROMOSOMAL INSTABILITY; CHROMOSOME STRUCTURE; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPE; MONOTHERAPY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CHROMOSOMAL INSTABILITY; FEMALE; GENETIC HETEROGENEITY; HUMANS; RECEPTOR, ERBB-2;

EID: 78049261497     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22781     Document Type: Article

References (86)

1. Anand S, Penrhyn-Lowe S, Venkitaraman AR. 2003. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3: 51-62.
2. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L. 2007. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 13: 2061-2067.
3. Aoki K, Tamai Y, Horiike S, Oshima M, Taketo MM. 2003. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/- compound mutant mice. Nat Genet 35: 323-330.
4. Bartlett JM, Desmedt C, Munro A, O'Malley F, Larsimont D, Di Leo A, Cameron D, Isola J, Shepherd L, Twelves C, Pritchard KI. 2009. Chromosome 17 polysomy: A unifying hypothesis underlying benefit from adjuvant anthracyclines? Cancer Res 69 (suppl.2): 11.
5. Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ. 2010. Predictive markers of anthracycline benefit: A prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 11: 266-274.
6. Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P. 2005. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23: 2162-2171.
7. Bouchet BP, Bertholon J, Falette N, Audoynaud C, Lamblot C, Puisieux A, Galmarini CM. 2007. Paclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype. Br J Cancer 97: 1218-1224.
8. Brunelli M, Manfrin E, Martignoni G, Miller K, Remo A, Reghellin D, Bersani S, Gobbo S, Eccher A, Chilosi M, Bonetti F. 2009. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: Evaluation according to ASCO/CAP criteria. Am J Clin Pathol 131: 678-682.
9. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B. 1998. Mutations of mitotic checkpoint genes in human cancers. Nature 392: 300-303.
10. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. 1999. Genetic instability and darwinian selection in tumours. Trends Cell Biol 9: M57-M60.
11. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. 2006. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38: 1043-1048.
12. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. 2006. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5(9): 1001-1007.
13. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF. 2008. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26: 5544-5552.
14. Diaz-Rodriguez E, Sotillo R, Schvartzman JM, Benezra R. 2008. Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo. Proc Natl Acad Sci USA 105: 16719-16724.
15. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF, Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K, Davies S, Guintoli T, Crowder R, Tao Y, Snider JE, Smith SM, Dukes AF, Sanderson GE, Pohl CS, Delehaunty KD, Fronick CC, Pape KA, Reed JS, Robinson JS, Hodges JS, Schierding W, Dees ND, Shen D, Locke DP, Wiechert ME, Eldred JM, Peck JB, Oberkfell BJ, Lolofie JT, Du F, Hawkins AE, O'Laughlin MD, Bernard KE, Cunningham M, Elliott G, Mason MD, Thompson DM, Jr., Ivanovich JL, Goodfellow PJ, Perou CM, Weinstock GM, Aft R, Watson M, Ley TJ, Wilson RK, Mardis ER. 2010. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464: 999-1005.
16. Duesberg P, Stindl R, Hehlmann R. 2000. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalysed by aneuploidy. Proc Natl Acad Sci USA 97: 14295-14300.
17. Ehlers JP, Worley L, Onken MD, Harbour JW. 2008. Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res 14: 115-122.
18. Ellsworth RE, Ellsworth DL, Patney HL, Deyarmin B, Love B, Hooke JA, Shriver CD. 2008. Amplification of HER2 is a marker for global genomic instability. BMC Cancer 8: 297.
19. Ganem NJ, Godinho SA, Pellman D. 2009. A mechanism linking extra centrosomes to chromosomal instability. Nature 460(7252): 278-282.
20. Gasparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, Morabito A, Silingardi V, Torino F, Spada A, Zancan M, De Sio L, Caputo A, Cognetti F, Lambiase A, Amadori D. 2007. Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 101: 355-365.
21. Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR. 2008. Defining 'chromosomal instability'. Trends Genet 24: 64-69.
22. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P. 2008. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 100: 14-20.
23. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, Ng C, Franco SX, Chow LW, Arbushites MC, Casey MA, Berger MS, Stein SH, Sledge GW. 2008. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26: 2999-3005.
24. Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bundgen NK, Nicorici D, Kronenwett U, Rathnagiriswaran S, Mettu RK, Ma Y, Kruger S, Bruch HP, Auer G, Guo NL, Ried T. 2009. The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer 124: 1552-1564.
25. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL, Peters JM. 2003. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161: 281-294.
26. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. 2007. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357: 1496-1506.
27. Hudis CA. 2007. Trastuzumab-Mechanism of action and use in clinical practice. N Engl J Med 357: 39-51.
28. Isola J, Tanner M, Holli Kea. 2000. Amplification of topoisomerase II alpha is a strong predictor of response to epirubicin-based chemotherapy in HER-2/neu positive metastatic breast cancer. Breast Cancer Res Treat 64 (S15): Abstract 31.
29. Jin J, Woodgett JR. 2005. Chronic activation of protein kinase Bbeta/Akt2 leads to multinucleation and cell fusion in human epithelial kidney cells: Events associated with tumorigenesis. Oncogene 24: 5459-5470.
30. Juul N, Wang Y, Kim J-Y, Eklund AC, Li Q, Carlton VEH, Gerlinger M, Swanton C, Garber JE, Silver DP, Faham M, Richardson AL, Szallasi Z, Wang ZC. 2009. A genomic-profile derived summary measure of chromosomal breakpoints predicts response to treatment with the DNA-damaging agent cisplatin. San Antonio: SABCS.
31. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C. 2010. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: A retrospective analysis of five clinical trials. Lancet Oncol 11(4): 358-365.
32. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdottir K, Olsen KE, Mouridsen H, Ejlertsen B. 2005. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23: 7483-7490.
33. Kronenwett U, Huwendiek S, Ostring C, Portwood N, Roblick UJ, Pawitan Y, Alaiya A, Sennerstam R, Zetterberg A, Auer G. 2004. Improved grading of breast adenocarcinomas based on genomic instability. Cancer Res 64: 904-909.
34. Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB, Bast RC, Jr. 2005. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280: 2092-2104.
35. Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC, Jr. 2006. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle 5: 1654-1661.
36. Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D. 2002. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 62: 5703-5710.
37. Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW. 2005. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 124: 273-281.
38. Li L, Dutra A, Pak E, Labrie JE III, Gerstein RM, Pandolfi PP, Recht LD, Ross AH. 2009. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol 11: 9-21.
39. Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, Whitehead CM, Reynolds C, Salisbury JL. 2002. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 99: 1978-1983.
40. Marchio C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, Tan DS, Mackay A, Fenwick K, Tamber N, Bussolati G, Ashworth A, Reis-Filho JS, Sapino A. 2009. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 219: 16-24.
41. Mariani G, Fasolo A, De Benedictis E, Gianni L. 2009. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 6: 93-104.
42. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. 2005. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23: 4265-4274.
43. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O'Neil J, Gutierrez A, Ivanova E, Perna I, Lin E, Mani V, Jiang S, McNamara K, Zaghlul S, Edkins S, Stevens C, Brennan C, Martin ES, Wiedemeyer R, Kabbarah O, Nogueira C, Histen G, Aster J, Mansour M, Duke V, Foroni L, Fielding AK, Goldstone AH, Rowe JM, Wang YA, Look AT, Stratton MR, Chin L, Futreal PA, DePinho RA. 2007. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447: 966-971.
44. McClelland SE, Burrell RA, Swanton C. 2009. Chromosomal instability: A composite phenotype that influences sensitivity to chemotherapy. Cell Cycle 8: 3262-3266.
45. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A. 2009. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1: 315-322.
46. Michel LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W, Dobles M, Sorger PK, Murty VV, Benezra R. 2001. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 409: 355-359.
47. Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL. 2007. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: Tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 25: 5418-5425.
48. Moelans CB, de Weger RA, van Diest PJ. 2009. Absence of chromosome 17 polysomy in breast cancer: Analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 120(1): 1-7.
49. Montagna C, Andrechek ER, Padilla-Nash H, Muller WJ, Ried T. 2002. Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene 21: 890-898.
50. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI. 2009. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101: 644-650.
51. Ott K, Vogelsang H, Mueller J, Becker K, Muller M, Fink U, Siewert JR, Hofler H, Keller G. 2003. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 9: 2307-2315.
52. Pack SD, Alper OM, Stromberg K, Augustus M, Ozdemirli M, Miermont AM, Klus G, Rusin M, Slack R, Hacker NF, Ried T, Szallasi Z, Alper O. 2004. Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line. Cancer Res 64: 789-794.
53. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN. 2006. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354: 2103-2111.
54. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B. 2008. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26: 736-744.
55. Pusztai L. 2007. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol 18 (Suppl 12): xii15-xii20.
56. Reddy SK, Rape M, Margansky WA, Kirschner MW. 2007. Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation. Nature 446: 921-925.
57. Roberts JR, Allison DC, Donehower RC, Rowinsky EK. 1990. Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Res 50: 710-716.
58. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684.
59. Roschke AV, Kirsch IR. 2005. Targeting cancer cells by exploiting karyotypic complexity and chromosomal instability. Cell Cycle 4: 679-682.
60. Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Scudiero DA, Weinstein JN, Kirsch IR. 2003. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 63: 8634-8647.
61. Roschke AV, Lababidi S, Tonon G, Gehlhaus KS, Bussey K, Weinstein JN, Kirsch IR. 2005. Karyotypic "state" as a potential determinant for anticancer drug discovery. Proc Natl Acad Sci USA 102: 2964-2969.
62. Schmidt M, Budirahardja Y, Klompmaker R, Medema RH. 2005. Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep 6: 866-872.
63. Schneeweiss A, Sinn HP, Ehemann V, Khbeis T, Neben K, Krause U, Ho AD, Bastert G, Kramer A. 2003. Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression. Int J Cancer 107: 346-352.
64. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S. 2009. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461: 809-813.
65. Shin SJ, Hyjek E, Early E, Knowles DM. 2006. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray. Int J Surg Pathol 14: 279-284.
66. Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, Gass JS, Kennedy TA, Fenton MA. 2009. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: A Brown University Oncology Group Study. J Clin Oncol 27: 4693-4700.
67. Slamon D. 2006. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. 29th Annual SABCS 2006 General Session 2 Abstract 52.
68. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 1987. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
69. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
70. Smith CA, Pollice AA, Gu LP, Brown KA, Singh SG, Janocko LE, Johnson R, Julian T, Hyams D, Wolmark N, Sweeney L, Silverman JF, Shackney SE. 2000. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: Evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. Clin Cancer Res 6: 112-126.
71. Sotillo R, Schvartzman JM, Socci ND, Benezra R. 2010. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature 464: 436-440.
72. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerod A, Russnes HE, Foekens JA, Reis-Filho JS, van't Veer L, Richardson AL, Borresen-Dale AL, Campbell PJ, Futreal PA, Stratton MR. 2009. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462: 1005-1010.
73. Sudo T, Nitta M, Saya H, Ueno NT. 2004. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64: 2502-2508.
74. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, Elustondo F, Chang J, Temple J, Ahmed AA, Brenton JD, Downward J, Nicke B. 2007. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11: 498-512.
75. Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, Hardcastle T, Lee A, Roy R, East P, Kschischo M, Endesfelder D, Wylie P, Kim SN, Chen JG, Howell M, Ried T, Habermann JK, Auer G, Brenton JD, Szallasi Z, Downward J. 2009. Chromosomal instability determines taxane response. Proc Natl Acad Sci USA 106(21): 8671-8676.
76. Szollosi J, Balazs M, Feuerstein BG, Benz CC, Waldman FM. 1995. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 55: 5400-5407.
77. Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D. 2002. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 9: 993-1004.
78. Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF. 2009. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 27: 3881-3886.
79. Valabrega G, Montemurro F, Aglietta M. 2007. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18: 977-984.
80. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. 2002. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
81. Walther A, Houlston R, Tomlinson I. 2008. Association between chromosomal instability and prognosis in colorectal cancer: A meta-analysis. Gut 57: 941-950.
82. Wang H, Hu X, Ding X, Dou Z, Yang Z, Shaw AW, Teng M, Cleveland DW, Goldberg ML, Niu L, Yao X. 2004. Human Zwint-1 specifies localization of Zeste White 10 to kinetochores and is essential for mitotic checkpoint signaling. J Biol Chem 279: 54590-54598.
83. Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T, Deng CX. 2006. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25: 7148-7158.
84. Weaver BA, Cleveland DW. 2005. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 8: 7-12.
85. Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah RK, Gorre ME, Mohammed MS, Gunn SR. 2009. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 22: 1169-1175.
86. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC. 1998. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 2: 581-591.